Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873012 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL86240 | 0.84 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL7303163 | 0.84 | HDAC3 (0.86) | TRPV1NAMPT | |
| SCHEMBL5934260 | 0.84 | TRPV1 (0.68) | TRPV1NAMPT | |
| SCHEMBL12044572 | 0.83 | PTPN1 (0.70) | TRPV1 | |
| SCHEMBL3872137 | 0.83 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL3881001 | 0.83 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL3873424 | 0.83 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL3880343 | 0.83 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5934750 | 0.82 | TRPV1 (1.00) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | claimed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | claimed |
| US-7595332-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBOTT LABORATORIES (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBVIE INC. | 2006-06-08 | — | — | US | disclosed |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | TRPV1 53/4885NAMPT 2308/4885 |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | TRPV1, OPRL1, AVPR2 | TRPV1 1/4885NAMPT 1428/4885 |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, AVPR1A | TRPV1 1/4885NAMPT 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.